Influvactetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

The active ingredient consists of inactivated antigens from the B/Phuket/3073/2013‑like and B/Austria/1359417/202 influenza B strains. After injection, these antigens are taken up by immune cells, prompting the production of strain‑specific neutralizing antibodies and memory cells that provide active immunity against future exposure to the matching influenza B viruses.

The prescribing healthcare professional determines the appropriate dose for each patient. Typically, a single intramuscular or subcutaneous injection is given each influenza season, but the exact volume and schedule are set by the clinician based on age, health status, and local immunization guidelines.

Safety data for Influvactetra in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits and risks before administration. Pregnant or nursing individuals should discuss vaccination with their physician to decide whether the vaccine is appropriate for their specific situation.

To place an order, submit an enquiry on the Influvactetra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Influvactetra specifically targets two contemporary influenza B lineages, offering strain‑matched protection. Compared with quadrivalent vaccines that also include influenza A strains, Influvactetra focuses solely on B‑type immunity, which may be advantageous in settings where B‑virus circulation predominates or where a B‑only formulation is preferred.

Influvactetra must be stored at 2‑8 °C in a refrigerator. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and handling is essential to preserve vaccine potency.

The vaccine is given by a qualified healthcare professional as a single intramuscular or subcutaneous injection, usually into the deltoid muscle of the upper arm. The injection site should be cleaned with an appropriate antiseptic before administration, and the patient should be observed for a short period afterward for any immediate reactions.

The most serious adverse events reported include severe allergic reactions such as anaphylaxis and rare neurological conditions like Guillain‑Barré syndrome. High fever or seizures may also occur, particularly in young children. Prompt medical attention is required if any of these symptoms develop after vaccination.

Individuals with a known severe allergy to any component of the vaccine, including egg proteins, should avoid it. Those who have experienced a previous anaphylactic reaction to an influenza B vaccine, as well as infants younger than six months, are also contraindicated. Consultation with a healthcare provider is essential for anyone with underlying health concerns.